V

PriceVerona Pharma

VRNA

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Historical stock price chart and annual return over the past years

1,327%

5 years

% Total

VRNA
70%

5 years

Annual Return

VRNA